In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be ...

Geographic atrophy can cause a 2 to 3 line loss in visual acuity within 36 months. 18.9% of eyes with GA developed neovascular age-related macular degeneration within 36 months. Eyes with fellow-eye ...

(Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe, progressive central vision loss and is a leading ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan) for the ...

Spectral domain optical coherence tomography demonstrates superiority over fluorescein angiography and color imaging for detecting fibrosis in eyes with neovascular age-related macular degeneration.

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular degeneration (nAMD) in eyes with geographic atrophy (GA) found that GA can ...

(Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy ...

announced that the Therapeutic Goods Administration (TGA) in Australia has approved its treatment SYFOVRE® (pegcetacoplan) for adult patients suffering from geographic atrophy (GA) secondary to ...